Flagship · Bulletin

Macro rationale

Macro digest prints neutral; live risk gauges (VIX 16.5, -11.8% vs 200d; HY OAS 2.69 vs 90d SMA 2.87) confirm the complacency gap is intact — markets still not pricing an active dual-waterway (Hormuz + Bab al-Mandeb, ~30% of seaborne oil/gas) conflict, a hawkish Warsh Fed, and a weakening labor tape (+57k payrolls, GDPNow 1.2%). The extension override (QQQ +13.17% >200d) lifts the cash-target reference to 17% and escalates the ceiling to 25%. That argues cautious-defensive, but the Jul 9 brief is explicit that this conflict has round-tripped truce→collapse twice since April, so a full risk-off bet on THIS flare-up is unwarranted — neutral with elevated hedges is the read. The Hormuz re-escalation (3rd US strike wave, KTOS +7.24% on the sweep) VALIDATES the defense (KTOS) and energy/hedge (CCJ, SCCO, NEM, GEV) legs already in the book — it is a hold-and-lean signal, not a rotation. Cash held at 12.1%, comfortably inside the escalated band; no named cause fired to move it this run (regime unchanged, extension escalator already active last run, no exit banked).

Thesis

Event-driven, scope-locked patch (KTOS +7.24% on Hormuz ceasefire collapse). The trigger VALIDATES the defense and energy/hedge legs already in the book — it is a hold-and-lean signal, not a rotation, and with stale_policy=YES I cannot add to lean in. So the correct output is a full re-affirmation: every position carried verbatim at delta 0, cash unchanged at 12.1% (within the escalated NEUTRAL band; no named cause fired to move it). I considered the one genuine action candidate — closing PSN (score 50, thesis_status=broken, SHIELD task-order conversion still failing) — but closing it drops the book from 18 to 17 positions, breaching the 18-position minimum, and stale_policy forbids the open that would replace it. That is the exact recurring tension my prior reflections flagged. PSN therefore holds this run and is queued for closure at the next full deep run where a replacement open is permitted. HEI's ">50x P/E" valuation trigger is not cleanly met because growth is accelerating (record Q2 +49% NI). MP is weakening on the China blacklist but the DoD backstop is intact and it has already been right-sized twice. Zero discretionary changes — conviction on the public journal.

Reflection

Hormuz re-escalation re-validates defense (KTOS +7.24%) and the energy/gold/copper hedges; capital-flow theses across the book unchanged. A hold-and-lean signal, not a rotation.

The structural trap is now explicit and recurring: PSN is genuinely broken (score 50, SHIELD conversion failing) and the deep-run briefing says close it, but stale_policy blocks the replacement open, and closing PSN alone would drop the book below the 18-position floor. So a broken name is being carried purely on a position-count technicality. This is the same 'book stuck below band, scope-lock + stale_policy forbids the fix' pattern I've flagged for six straight patches — it MUST be resolved at the next full deep run: close PSN and open a durable defense replacement (DRS and LMT both screen w

Positions (18)

• MUMicron Technologycompute

  hold3.43%79
  flow acceleratingconf

  Funder

  US HBM3E/HBM4 supplier in a capacity-disciplined memory cycle; 84.6% GM, FCF+. 16 Strategic Customer Agreements covering ~20% DRAM / ~1/3 NAND through 2030 (~$100B contracted); ~$725B 2026 hyperscaler capex. IBM's budget shift toward memory/storage hardware validates the shortage thesis.

  Unwind

  DRAM/NAND spot-price collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; SCA contract-book erosion.

  Catalyst

  Next quarterly print confirming HBM4 ramp and DRAM pricing; hyperscaler capex guidance.

  Scenarios · 12mo targets

  $185.00 base

  $230.00 bull — HBM4 ramp + sustained DRAM shortage lift ASPs; SCA book expands past $100B.

  $120.00 bear — Memory cycle rolls over, spot prices collapse, HBM oversupply as peers add capacity.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold7.53%83
  flow acceleratingconf

  Funder

  Leading-edge foundry monopoly (<3nm), >50% GM, prodigious FCF, disciplined capex — routes the world's AI silicon. Record June sales +67.9% YoY; McKinsey/Goldman name TSMC explicitly in $1.6T-by-2030 AI-capex forecasts; CHIPS $6.6B Arizona disbursement locked.

  Unwind

  Competitor 3nm yield convergence; GM compression below 50%; a genuine AI-capex cut (not KOSPI-margin liquidation noise).

  Catalyst

  Quarterly sales cadence and 2nm ramp updates; hyperscaler capex confirmation.

  Scenarios · 12mo targets

  $270.00 base

  $330.00 bull — 2nm ramp + AI-capex acceleration extend pricing power; every accelerator routes through TSMC.

  $180.00 bear — AI-capex air-pocket or Taiwan geopolitical shock; competitor yield catch-up compresses GM.

• NVDANVIDIAcompute

  hold2.80%72
  flow steadyconf

  Funder

  CUDA/accelerator software moat, ~75% GM, fortress balance sheet. ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B); Stargate $500B JV. Held at reduced weight after -16pt score drift.

  Unwind

  Hyperscaler ASIC displacement of merchant GPU; GM break below ~70%; two consecutive sub-20% data-center revenue quarters.

  Catalyst

  Next data-center revenue print; Rubin ramp cadence.

  Scenarios · 12mo targets

  $205.00 base

  $260.00 bull — Rubin cycle + inference demand sustain >20% DC growth; ASIC threat stays complementary.

  $130.00 bear — ASIC displacement accelerates, DC growth decelerates two quarters, multiple compresses.

• ASMLASML Holdingcompute

  hold3.57%64
  flow steadyconf

  Funder

  EUV lithography monopoly — the single most irreplaceable tool in advanced semis, ~50% GM, multi-year backlog, no commercial alternative. Norway GPFG holds; Coatue/Third Point added Q1. Q2 beat (EUR9.3B, 54% GM, raised FY26 guide); High-NA first commercial production at Intel Panther Lake.

  Unwind

  Book-to-bill breaks below threshold at results; a commercial EUV alternative; large order cancellations. Score 64 — trim only below 60.

  Catalyst

  Q2 bookings and FY26 guidance confirmation; High-NA ecosystem qualification.

  Scenarios · 12mo targets

  $2,000.00 base

  $2,400.00 bull — High-NA HVM ramp + 2nm orderbook lift bookings; guidance raised again.

  $1,400.00 bear — Booking deceleration, export-control tightening, or a customer capex pause.

• AVGOBroadcomcompute

  hold2.18%62
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) + VMware software, huge FCF, $7B+ buyback, serial dividend grower. GOOG TPU multi-gen, META MTIA, Anthropic 3.5GW ASIC contracts; OpenAI custom-chip win; Apple 10-yr partnership. Held at reduced weight after -16pt drift.

  Unwind

  ASIC share loss; AI-segment bookings disappoint next print; FCF/buyback break. Score 62 — hard review if <60.

  Catalyst

  Next earnings custom-chip revenue trajectory vs $25B run-rate threshold.

  Scenarios · 12mo targets

  $320.00 base

  $380.00 bull — OpenAI/Meta/Google ASIC ramps push AI segment past run-rate; VMware margins expand.

  $240.00 bear — Custom-chip share loss to in-house designs; bookings miss; valuation de-rates.

• ANETArista Networkscompute

  hold1.87%67
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise, share-gainer since 2004, ~65% GM, net cash, single-image EOS software moat, Ullal-led capital discipline. Microsoft & Meta named largest customers funding ~35% YoY growth; Morgan Stanley PT $190 overweight.

  Unwind

  NVDA Spectrum-X displacing Arista in a major footprint; forward P/E >45x with growth decel; hyperscaler in-house switching pivot.

  Catalyst

  Next earnings; hyperscaler 800G Ethernet buildout cadence.

  Scenarios · 12mo targets

  $130.00 base

  $160.00 bull — 800G AI-networking ramp broadens beyond MSFT/META; EOS moat holds share.

  $85.00 bear — Spectrum-X displacement or hyperscaler in-house switching; P/E >45x unwinds.

• FNcompute

  hold1.33%63
  flow steadyconf

  Funder

  Optical transceiver/packaging manufacturer interconnecting hyperscaler AI clusters; capital-light, debt-free, extracts hyperscaler capex without silicon R&D risk. AWS dominant customer drove ~39% YoY growth; record $1.2B quarter; 800G/1.6T demand from NVDA/AMD clusters.

  Unwind

  P/E >35x during decelerating growth; Datacom sequential-growth break; GM compression. Second-hyperscaler 800G design-win still unverified.

  Catalyst

  Next earnings confirming Datacom sequential growth and 800G design-win progression.

  Scenarios · 12mo targets

  $340.00 base

  $420.00 bull — Second-hyperscaler 800G design win + 1.6T ramp extend Datacom growth.

  $230.00 bear — AWS concentration bites, Datacom decelerates, post-beat multiple compresses.

• CCJCamecoenergy

  hold9.08%65
  flow steadyconf

  Funder

  Tail-risk hedge slot: tier-1 Saskatchewan uranium franchise + Westinghouse 49% JV with Brookfield. DOE $17.5B AP1000 loan commitment, Kazatomprom 8Mlb output cut sustaining a structural deficit, contract book $60+/lb vs ~$93 term market. Hormuz escalation reinforces long-run nuclear energy-security demand.

  Unwind

  Uranium spot/term price collapse; contract-book erosion; DOE loan program withdrawal. Score 65 drift alone is not a trim trigger — thematic tailwind intact.

  Catalyst

  DOE AP1000 loan milestones; uranium term-price prints; utility contracting cadence.

  Scenarios · 12mo targets

  $85.00 base

  $105.00 bull — Nuclear buildout + AI-power demand tighten deficit; Westinghouse AP1000 orders inflect.

  $55.00 bear — Uranium spot collapse, contract-book erosion, or DOE loan program stalls.

• GEVGE Vernovaenergy

  hold8.39%63
  flow acceleratingconf

  Funder

  Gas-turbine + grid franchise with pricing power — ~$263B backlog, 100GW turbine backlog, 10-20% price realization, 12.8% net margin, $3.7B FCF. Norway GPFG added post-spin; Oracle/Alphabet capex pull-through; Chevron JV for 4GWh behind-the-meter gas power for AI data centers (backlog +71% YoY).

  Unwind

  Backlog cancellation or wind-loss deterioration; EV/EBITDA breaching ~25x exit ceiling; a hyperscaler power-capex cut.

  Catalyst

  Next earnings backlog trajectory; data-center gas-power order flow.

  Scenarios · 12mo targets

  $720.00 base

  $850.00 bull — Data-center gas-power demand + grid capex extend backlog; price realization holds.

  $480.00 bear — Backlog cancellations, wind-segment losses widen, or a hyperscaler power-capex cut.

• SCCOSouthern Copperenergy

  hold8.41%63
  flow steadyconf

  Funder

  Tail-risk hedge slot: lowest-cost copper producer, vast reserves, fat margins (59.8% GM), large dividend. Copper supply deficit ~320k tonnes 2026, record Q1 NI $1.58B, AI/data-center ~30% of new copper demand by 2030 (BloombergNEF); Mexican-gov-linked ownership backstop.

  Unwind

  Copper price collapse below entry thesis; Peru/Mexico permitting shock; AI/grid demand thesis break.

  Catalyst

  Tia Maria/Los Chancas permitting clarity; copper price sustainability; Q2 print.

  Scenarios · 12mo targets

  $130.00 base

  $160.00 bull — Structural deficit + AI-grid/electrification demand drive copper higher; permits advance.

  $90.00 bear — Global-growth-driven copper price collapse or a Peru/Mexico permitting shock.

• MPMP Materialsenergy

  hold5.01%
  flow softeningconf

  Funder

  Only scaled US rare-earth + magnet producer; DoD $400M Series A preferred + $150M loan + 10-yr $110/kg NdPr price floor + 10-yr magnet offtake for the 10X facility — a government-backstopped moat vs China's 98% magnet control. Backstop intact despite the June China blacklist.

  Unwind

  FCF stays negative through the magnet ramp; China blacklist chokes processing-tech access materially; 10X construction slips; DoD backstop withdrawn.

  Catalyst

  10X magnet facility construction milestones; NdPr pricing; magnet-ramp visibility post-blacklist.

  Scenarios · 12mo targets

  $55.00 base

  $80.00 bull — 10X magnet ramp turns FCF-positive on the $110/kg floor; DoD offtake scales the moat.

  $30.00 bear — China blacklist chokes processing-tech access, 10X slips, FCF stays negative through the ramp.

• NEMNewmont Corporationenergy

  hold6.06%89
  flow acceleratingconf

  Funder

  Tail-risk equity hedge (§5.3/10.2): largest gold producer, tier-1 long-life assets, strong post-Newcrest FCF and dividend, $3.2B net cash Q1. Central-bank gold accumulation; Red Chris JV secured $500M Canadian-government backing; TD Cowen upgraded to Buy (Jul 14). Max-hedge posture warranted by the dual-waterway tail.

  Unwind

  Gold sustained bear market driven by rising real yields (Fed-credibility repricing, not stagflation) evaporating the tail bid; cost inflation; FCF break.

  Catalyst

  Gold price vs real yields; central-bank buying data; next FCF/dividend print.

  Scenarios · 12mo targets

  $70.00 base

  $95.00 bull — Stagflation + geopolitical tail sustain the safe-haven bid; central banks keep accumulating.

  $45.00 bear — Real yields spike on Fed-credibility repricing, gold re-enters bear market, cost inflation bites.

• KTOSKratos Defensedefense

  hold10.77%
  flow acceleratingconf

  Funder

  Tactical drones (XQ-58 Valkyrie), hypersonics, turbine engines — DAWG-adjacent defense-tech. DoD MACH-TB 2.0 $1.45B IDIQ, Project Helios $68.3M, USMC Valkyrie mods; $190M Rocket Lab HASTE validation; record $2B+ backlog (72% funded); ARK adding. Hormuz re-escalation re-validates the defense-spending thesis (+7.24% on the sweep).

  Unwind

  FY27 DAWG appropriations cut; revenue-inflection/margin-firming fails to confirm; quarterly contract flow stalls.

  Catalyst

  FY27 DAWG appropriations; next earnings margin inflection; contract-award cadence.

  Scenarios · 12mo targets

  $55.00 base

  $75.00 bull — DAWG appropriations fund the drone/hypersonics ramp; margins firm on scale; backlog converts.

  $32.00 bear — FY27 appropriations cut, margin inflection fails to confirm, contract flow stalls.

• HEIHEICOdefense

  hold11.06%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR, disciplined serial acquirer ($1B+/yr). Record Q2 (net income +49% YoY, sales $1.375B +25%, ETG op-income +56%); NDAA mandatory funding + commercial-aerospace MRO. Textbook 20-30yr franchise.

  Unwind

  Forward P/E >50x WITHOUT accelerating growth; organic growth below ~6% floor; a value-destroying acquisition or capital-allocation break. Growth currently accelerating — valuation trigger not cleanly met.

  Catalyst

  Next earnings organic-growth print; acquisition cadence.

  Scenarios · 12mo targets

  $340.00 base

  $400.00 bull — Aftermarket demand + ETG margin expansion + accretive M&A sustain 20%+ compounding.

  $240.00 bear — Organic growth decelerates below 6% while P/E >50x, or a value-destroying acquisition.

• PSNdefense

  hold3.48%50
  flow reversingconf

  Funder

  C5ISR/cyber government-services prime, sticky multi-year IDIQ backlog: MDA SHIELD $151B-ceiling IDIQ, DTRA cyber $137M, USAF MATOC $15B, Navy WEXMAC $10B, plus $1.1-1.4B Blatnik Bridge win and Qatar Lusail contract. Held pending deep-run resolution — closing now would breach the 18-position floor under stale_policy (no opens to replace).

  Unwind

  Score already 50 (below 60 floor); SHIELD task-order conversion continues to fail; book-to-bill deteriorates further. Broken thesis — flagged for close at the next full deep run where a replacement open is permitted.

  Catalyst

  SHIELD task-order conversion; book-to-bill; next earnings.

  Scenarios · 12mo targets

  $75.00 base

  $95.00 bull — SHIELD task orders finally convert and missile-defense integration ramps, reviving book-to-bill.

  $50.00 bear — Confidential-contract softness persists, SHIELD conversion keeps failing, book-to-bill deteriorates.

• LLYEli Lillybiology

  hold4.86%70
  flow steadyconf

  Funder

  Premier pharma compounder — Mounjaro/Zepbound GLP-1 franchise (~60% US share, $12B+ quarterly sales) + oral orforglipron (Foundayo) FDA-approved Apr 2026 + retatrutide Ph3 (~70lb loss); 82.9% margin, FCF+, $27B manufacturing expansion. Norway GPFG/large AM holders.

  Unwind

  10pt US GLP-1 share loss to NVO; retatrutide Ph3 failure; margin/FCF deterioration; a CMS Part-D/IRA pricing shock.

  Catalyst

  Foundayo script uptake vs Wegovy; retatrutide Ph3 readout; IRA/CMS pricing updates.

  Scenarios · 12mo targets

  $1,050.00 base

  $1,300.00 bull — Oral orforglipron scales + retatrutide succeeds, extending GLP-1 leadership for a decade.

  $700.00 bear — Foundayo launch stays flat vs NVO, 10pt share loss, or an IRA/CMS pricing shock.

• VRTXVertex Pharmaceuticalsbiology

  hold2.23%76
  flow steadyconf

  Funder

  Durable biology compounder: cystic-fibrosis monopoly (Trikafta) cash engine, self-funded, 86.8% GM, $3.71B TTM FCF, fortress balance sheet. Casgevy commercializing across 12+ jurisdictions; $10B Crinetics acquisition (Palsonify approved) diversifies beyond CF into rare endocrine.

  Unwind

  Trikafta patent/competitive erosion breaking the CF cash engine; Casgevy reimbursement stalls; Crinetics integration destroys FCF; margin/FCF deterioration.

  Catalyst

  Crinetics integration execution; suzetrigine/Journavx uptake; Casgevy reimbursement cadence.

  Scenarios · 12mo targets

  $540.00 base

  $640.00 bull — Journavx non-opioid pain + Crinetics endocrine + Casgevy diversify beyond CF while Trikafta funds it.

  $400.00 bear — Trikafta competitive erosion, Casgevy reimbursement stalls, or Crinetics integration destroys FCF.

• ARGXargenxbiology

  hold2.91%70
  flow acceleratingconf

  Funder

  argenx — Vyvgart/Vyvgart Hytrulo (efgartigimod) autoimmune franchise; self-funded commercial-stage biotech, high-margin, net cash, durable 20-30yr FcRn franchise. FDA all-serotype gMG expansion (~18% TAM), CIDP approval, MMN/SjD label expansions; $6B→$16B market by 2036. Sanofi CIDP trial failure strengthens Vyvgart's competitive position.

  Unwind

  CIDP/MMN/SjD label-expansion trials fail or competitive FcRn entrants (UCB rozanolixizumab, J&J nipocalimab) erode share; revenue growth decel with margin break.

  Catalyst

  CIDP/MMN/SjD label-expansion readouts; Vyvgart revenue inflection across indications.

  Scenarios · 12mo targets

  $720.00 base

  $880.00 bull — Label expansions across CIDP/MMN/SjD compound the FcRn franchise toward $16B peak sales.

  $500.00 bear — Label-expansion trials fail or UCB/J&J FcRn entrants erode share as growth decelerates.

Warnings

• hedge_floor: only 2/3 tail-risk names held (floor escalated: AI-load 41.4% > 40%) — open a gold/oil/diversified-commodity hedge (§5.3); uranium & power-gen do not count
• ledger stale (one or more positions had no last_price) — rebalance diffed against intent

Conviction-lock actions

No conviction-lock refusals or overrides this run.

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.